This R21 application proposes a novel use of naltrexone as treatment for Pathological Gambling Disorder (PGD) patients with severe urge symptoms. Although PGD is a prominent and growing social problem, there is no established drug treatment for this disorder. Our preliminary investigations demonstrate statistically significant findings that an opioid antagonist, may serve as a viable treatment option for PGD patients with severe urges. In 1994, naltrexone was approved to treat alcoholism (at a dose limited to 50 mg/day, but the use of naltrexone has since languished. In an effort to further pursue the use of naltrexone, we adopted a novel alternative approach. ? ? First, we focused our efforts only on a subset of PGD patients who had severe urge symptoms, as opposed to the entire PGD population. Second, we tested naltrexone at doses higher than 50 mg/day (up to 250 mg/day). Third, we addressed the side effect of hepatic transaminase revelation, an established adverse effect of naltrexone at doses above 50 mg/day, and we found a solution, such that dosages up to 250 mg/day were well tolerated and safe during an 11-week time period of use. In our three preliminary investigations, we found statistically significant results in our case study, open study, and double blind study, showing that naltrexone doses above 50 mg/day are effective in treating PGD patients with severe urges. ? ? We present the design of our proposed double-blind study, placebo-controlled, dose-finding study, which will expand upon our preliminary work and will establish the optimal dose for efficacy, whether efficacy is maintained for 16 weeks, and whether efficacy is disrupted in a male: female ratio analogous to that of the PGD population in the U.S. The implications of our study expand from PGD to other impulse control disorders, including compulsive shopping, kleptomania and possible alcoholism.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21MH065920-03
Application #
6738125
Study Section
Special Emphasis Panel (ZRG1-BBBP-5 (01))
Program Officer
Breiling, James P
Project Start
2002-08-15
Project End
2005-11-30
Budget Start
2004-06-01
Budget End
2005-11-30
Support Year
3
Fiscal Year
2004
Total Cost
$154,742
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Psychiatry
Type
Schools of Medicine
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Grant, Jon E; Kim, Suck Won; Odlaug, Brian L et al. (2009) Late-onset pathological gambling: clinical correlates and gender differences. J Psychiatr Res 43:380-7
Grant, Jon E; Kim, Suck Won; Hollander, Eric et al. (2008) Predicting response to opiate antagonists and placebo in the treatment of pathological gambling. Psychopharmacology (Berl) 200:521-7
Grant, Jon E; Kim, Suck Won; Odlaug, Brian L et al. (2008) Daily Tobacco Smoking in Treatment-Seeking Pathological Gamblers: Clinical Correlates and Co-occurring Psychiatric Disorders. J Addict Med 2:178-184
Grant, Jon E; Kim, Suck Won; Hartman, Boyd K (2008) A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling urges. J Clin Psychiatry 69:783-9
Grant, Jon E; Kim, Suck Won (2005) Quality of life in kleptomania and pathological gambling. Compr Psychiatry 46:34-7